- Report
- June 2023
- 95 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- November 2024
Japan, United States, ... Japan, United States, Europe
From €1390EUR$1,450USD£1,161GBP
- Report
- October 2024
Global
From €3355EUR$3,500USD£2,804GBP
- Company Profile
- September 2024
From €1390EUR$1,450USD£1,161GBP
- Company Profile
- September 2024
From €911EUR$950USD£761GBP
- Report
- August 2024
- 61 Pages
Germany
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 58 Pages
France
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 101 Pages
United States
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 64 Pages
United Kingdom
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 56 Pages
Spain
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 60 Pages
Japan
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 57 Pages
Italy
From €3595EUR$3,750USD£3,004GBP
- Report
- March 2022
Japan, United States, ... Japan, United States, Europe
From €1390EUR$1,450USD£1,161GBP

The Prostate Specific Antigen (PSA) Test is a diagnostic tool used to detect the presence of prostate cancer in men. It measures the amount of PSA, a protein produced by the prostate gland, in the blood. Elevated levels of PSA may indicate the presence of prostate cancer, although other conditions such as benign prostatic hyperplasia can also cause elevated PSA levels. The PSA Test is typically used in conjunction with other tests such as digital rectal examination and biopsy to confirm a diagnosis of prostate cancer.
The PSA Test market is a subset of the larger Diagnostics market, which includes a wide range of tests used to diagnose and monitor diseases. The Diagnostics market is highly competitive, with a variety of companies offering a range of products and services.
Some companies in the Prostate Specific Antigen Test market include Abbott Laboratories, Beckman Coulter, Siemens Healthineers, Roche Diagnostics, and Quest Diagnostics. Show Less Read more